Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Learn more about:
Related Clinical Trial
Effect of the Composition From Fish on Promoting Hair Growth Use of Botulinum Toxin in the Treatment of Androgenic Alopecia 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia Fractional Laser Versus Radiofrequency in Androgenetic Alopecia Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Hydraderm for Androgenic Alopecia Sham LaserCap vs. LaserCap SD vs. LaserCap HD+ Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia Activated PRP for Treatment of Androgenetic Alopecia To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19). Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series A Study to Evaluate the Efficacy and Safety of AD-208 A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia Low Level Light Device as a Primary Therapy for Androgenetic Alopecia the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending Topical Cetirizine in Androgenetic Alopecia in Females A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss Anti-Androgen Treatment for COVID-19 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss The Effect of Platelet Rich Plasma on Non-scarring Alopecia Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter HairDx Analytical Validation Study The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study To Evaluate the Pharmacokinetics and Safety of AD-208 The Utility of Platelet Rich Plasma in Hair Loss Computer-Assisted Versus Manual Hair Harvest Comparative Study Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) PAI-1 Expression in Non-scarring Hair Loss Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Cold Plasma to Treat Hair Loss Adipose-derived SVF for Treatment of Alopecia Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Photosensitization Study in Androgenetic Alopecia Point-of-Care Adipose-derived Cells for Hair Growth Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Modulated Light Therapy in Participants With Pattern Hair Loss Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia N-Acetyl-Cysteine for Treatment of AGA in Men Clinical Trial in Females for Female Pattern Hair Loss Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Treatment of Androgenetic Alopecia in Males and Females Microarray Analysis of Scalp Biopsies After Minoxidil Treatment Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Minoxidil Response Testing in Males With Androgenetic Alopecia Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Treatment of Androgenetic Alopecia in Females, 9 Beam Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Treatment of Androgenetic Alopecia in Males Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Treatment of Androgenetic Alopecia in Females, 12 Beam Nanofat Grafting for Treatment of Androgenetic Alopecia Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Treatment of Androgenic Alopecia in Males A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Androgenetic Alopecia and the JAK-STAT Pathway Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Brief Title

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single and Multiple Ascending Dose Administration

Brief Summary

      A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to
      evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical
      single ascending dose in healthy subjects and multiple ascending dose administration in
      subjects with androgenetic alopecia(AGA) or acne
    


Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Adverse event


Condition

Acne Vulgaris

Intervention

GT20029 Gel

Study Arms / Comparison Groups

 GT20029
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

152

Start Date

February 10, 2022

Completion Date

February 10, 2023

Primary Completion Date

September 10, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects who meet all of the following criteria can be enrolled into the study:

               1. For all(Cohort 1+ 2):

                    1. Aged 18 to 60 years old;

                    2. The subject or legally authorized representative give signed informed
                       consent which includes compliance with the requirements and restrictions
                       listed in the informed consent form (ICF) and in this protocol;

                    3. Understand and agree to comply with planned study procedures;

                    4. Subjects with a weight of ≥ 50 kg for male, a weight of ≥ 45 kg for female,
                       and a body mass index (BMI) between 19 and 30 kg/m2 (inclusive);

                    5. Subjects are able to communicate well with the investigator and understand
                       and comply with the requirements of the study

                    6. Considered healthy by the Principal Investigator, based on a detailed
                       medical history, full physical examination, clinical laboratory tests,
                       12-lead ECG and vital signs.

               2. For Cohort 1(single dose escalation):

                    1. Healthy subjects, male or non-pregnant female;

                    2. The subject's skin is healthy without damage or wound, tattoos and scars;

               3. For Cohort 2a(multiple dose escalation):

                    1. Male or non-pregnant female;

                    2. Subjects clinically diagnosed with grade I-III acne vulgaris as per the
                       Pillsbury International Modified Classification, and with an IGA score of
                       2-3;

                    3. Subject has used the same type and brand of make-up, other facial products
                       (exclusive of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel,
                       hair spray, mousse, etc.) for at least one (1) month prior to the Baseline
                       Visit and agrees to continue his/her other general skin and hair care
                       products and regimen for the entire study.

               4. For cohort 2b (multiple dose escalation)

                    1. Male;

                    2. Have a clinical diagnosis of mild to moderate androgenetic alopecia; rating
                       IIIv, IV and V on the modified Norwood Hamilton Scale, with a history of
                       ongoing hair loss;

                    3. Subject is willing to maintain the same hairstyle, hair length, and hair
                       color throughout the study;

               5. Negative COVID-19 results within 7 days prior first dosing

        Exclusion Criteria:

          -  Subjects will be excluded from study entry if any of the following exclusion criteria
             are present at screening:

               1. For all:

                    1. Prior allergy to the investigational drug or any components;

                    2. Use of drugs with the same target and mechanism as the investigational drug
                       (androgen receptor degradation agent) within 1 month prior to screening;

                    3. Any visible skin disease, damage or condition at the application site which,
                       in the opinion of the investigator, could compromise subject safety and/or
                       interfere with the evaluation of the test site reaction;

                    4. Clinically significant history of gastrointestinal, cardiovascular,
                       musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic,
                       bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or
                       drug hypersensitivity

                    5. Known or suspected malignancy;

                    6. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B
                       surface antigen (HBsAg), or hepatitis C antibody;

                    7. A hospital admission or major surgery within 30 days prior to screening;

                    8. Participation in any other investigational drug trial within 30 days prior
                       to screening;

                    9. A history of drug abuse within 6 months prior to screening or a positive
                       screen for drugs of abuse;

                   10. Subjects with an alcohol consumption of more than 14 units per week (1 unit
                       of alcohol ≈ 360 mL of beer or 45 mL of spirits containing 40% alcohol or
                       150 mL of wine) within 3 months prior to signing the informed consent form,
                       or subjects with a positive breath alcohol test result the day before dosing
                       (breath alcohol content > 0.0 mg/100 mL), or subjects cannot abstain from
                       alcohol during the study;

                   11. Subjects with a previous chronic consumption of excessive (more than 8 cups
                       a day, 1 cup = 200 mL) tea, coffee, or caffeine-containing beverages;

                   12. Subjects with a consumption of any food or beverages containing caffeine,
                       alcohol, xanthine or grapefruit (e.g., coffee, strong tea, chocolate, etc.)
                       within 48 hours prior to the first dose;

                   13. Subjects who have difficulty in blood collection or cannot tolerate
                       venipuncture or have a history of fear of needles and hemophobia;

                   14. Subjects with a blood donation history or blood loss of ≥ 200 mL within 3
                       months prior to the study, or who plan to donate blood or blood components
                       during the study or within 3 months after the end of the study;

                   15. Subjects who smoked more than 5 cigarettes per day within 3 months before
                       the study and who could not stop smoking during the entire study;

                   16. Donation or blood collection of more than 1 unit (approximate 450 mL) of
                       blood (or blood products) or acute loss of blood during the 90 days prior to
                       screening;

                   17. Use of prescription or over-the-counter (OTC) medications, and herbal
                       (including St John's Wort, herbal teas, garlic extracts) within 14 days
                       prior to dosing (Note: Use of acetaminophen at < 3g/day is permitted until
                       24 hours prior to dosing);

                   18. An unwillingness to use highly effective contraceptive measures if engaging
                       in sexual intercourse with a partner of childbearing potential. Highly
                       effective measures include use of a condom and spermicide and, for female
                       partners, use of an intrauterine device (IUD), diaphragm with spermicide,
                       oral contraceptives, injectable progesterone, progesterone subdermal
                       implants, or a tubal ligation, and men or women who are unwilling to use
                       contraception throughout the study and until 1 month after the end of the
                       study.

                   19. Subjects who are employees or related personnel of the investigator, study
                       site, sponsor, and contract research organization;

                   20. Subjects who have other conditions that may affect compliance in the opinion
                       of the investigator, or who are unable to participate in the study for
                       his/her own reasons;

                   21. Subjects who are unable to communicate or cooperate with health care
                       professional due to neurological, psychiatric or language disorders

               2. For Cohort 2a (subjects with alopecia):

                    1. Subject has any dermatological disorders of the scalp in the target region
                       with the possibility of interfering with the application of the
                       investigational drug, such as fungal or bacterial infections, seborrheic
                       dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy;

                    2. Subject has any skin pathology or condition that, in the investigator's
                       opinion, could interfere with the evaluation of the investigational drug or
                       requires use of interfering topical, systemic (e.g., uncontrolled thyroid
                       disease, certain genetic disorders that involve hair growth or patterns), or
                       surgical therapy;

                    3. Subject has current or recent history (within 12 months) of hair weaves,
                       non-breathable wigs, or hair bonding;

                    4. Subject had scalp hair transplants at any time;

                    5. Subject has a history or active hair loss due to diffuse telogen effluvium,
                       alopecia areata, scarring alopecia, trichotillomania, or conditions/diseases
                       other than AGA;

                    6. Subject has a current or recent history (within six months) of severe
                       dietary or weight changes or has a history of eating disorder(s); if such
                       has resulted in hair loss refer to exclusion criterion #5;

                    7. Any disorder, including but not limited to, cardiovascular,
                       gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious,
                       endocrine, metabolic, haematological, psychiatric, or major physical
                       impairment that is not stable in the opinion of the Investigator and could
                       affect the safety of the subject throughout the study

               3. For Cohort 2b(acne)

                    1. Subject has greater than two (2) facial nodules.

                    2. Subject has nodulocystic acne.

                    3. Subject has facial hair that could interfere with the study assessments in
                       the opinion of the investigator.

                    4. Subject has used any of the following topical anti-acne preparations or
                       procedures on the face:

                         -  Topical anti-acne treatments including, but not limited to,
                            over-the-counter (OTC) acne cleansers or treatments, benzoyl peroxide,
                            antibiotics, azelaic acid, sulfa based products, corticosteroids and
                            salicylic acid within two (2) weeks of the initiation of treatment.

                         -  Retinoids, including tazarotene, adapalene, tretinoin, within four (4)
                            weeks of the initiation of treatment.

                         -  Light treatments, microdermabrasion, or chemical peels within eight (8)
                            weeks of the initiation of treatment.

                    5. Subject has used the following systemic anti-acne medications:

                         -  Corticosteroids (including intramuscular and intralesional injections)
                            within four (4) weeks of the initiation of treatment. Inhaled,
                            intranasal, or ocular corticosteroids are allowed if use is stable
                            (stable use is defined as dose and frequency unchanged for at least
                            four (4) weeks prior to the initiation of treatment).

                         -  Antibiotics within four (4) weeks of the initiation of treatment with
                            the exception of five (5) days or less of antibiotic therapy during
                            this period, BUT with no antibiotics use permitted within one (1) week
                            prior to the initiation of treatment.

                         -  Spironolactone within eight (8) weeks of the initiation of treatment
                            with the exception of five (5) days or less of spironolactone therapy
                            during this period, BUT with no spironolactone use permitted within one
                            (1) week prior to the initiation of treatment.

                         -  Retinoid therapy within six (6) months of the initiation of treatment.

                         -  Other systemic therapy which may materially affect the subject's acne
                            in the opinion of the investigator.

               4. For female subjects:

                    1. Pregnant, lactating women, or women who plan to become pregnant during the
                       study
      

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, 86-512-62639909, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT05428449

Organization ID

GT20029-US-1001


Responsible Party

Sponsor

Study Sponsor

Suzhou Kintor Pharmaceutical Inc,


Study Sponsor

, , 


Verification Date

June 2022